Background: Biomarkers have been related to the arrhythmia recurrence following
Relapses of AF post CA remain common, and many factors have been associated with AF progression and recurrence. 2 Based on clinical factors associated with arrhythmia recurrence post-CA, many clinical scoring systems have been proposed. 3 However, there is no general agreement of which score or risk factor is best.
Biomarkers such as NT-proBNP 4, 5 and CRP 6 have been involved in the development and recurrence of AF by inducing structural and electrical remodeling. 7 Chronic kidney disease (CKD) as defined by the eGFR is also reported as a predictor of AF recurrence post-CA. 8 Previous reports on these biomarkers generally evaluated their impact as a single predictor but no prior studies have investigated their cumulative impact for predicting arrhythmia recurrent post-CA when used in a cumulative manner.
In this study, we tested the hypothesis that concurrent measurement of several biomarkers reflecting different pathophysiological processes would improve the predictive value of arrhythmia recurrence post-CA. 
| ME TH ODS
This
| Definitions
Paroxysmal AF (PAF) was defined as AF that spontaneously terminated or with intervention within 7 days, persistent AF (PeAF) as AF that lasted ≥7 days, and longstanding PeAF (LSPeAF) as AF lasted >1 year. 2 The term "nonparoxysmal" AF (NPAF) included PeAF and
LSPeAF. AF types in this study were divided into PAF and NPAF. All Arrhythmia relapse recorded within the 3-month "blanking period"
after the ablation was defined as early recurrence (ER A cut-off value of each biomarker for predicting recurrence post-CA was tested using ROC analysis and was used to distinguish patients with "normal" or "abnormal" biomarker serum level. "Abnormal biomarker levels" were defined as BNP and CRP levels higher than the determined cut-off value from ROC analysis, or eGFR levels below the cut-off value.
For the categorical analyses, we scored patients as having 0, 1, 2, and 3 points for those with none, 1, 2, or 3 abnormal biomarker levels. Patients were divided into four groups according the different points and the baseline clinical characteristics and AF relapses post-CA were compared.
| Laboratory tests
Peripheral blood samples were collected from each patient who were fasting at the second morning after being hospitalized. 
| Ablation procedure
Anticoagulation therapy, AAD therapy, and exclusion of thrombosis procedure were performed following guideline recommendations. 10 Radiofrequency ablation procedures were described detailed as previously which in briefly following a stepwise protocol. The cryoballoon ablation procedure was consecutively performed as previously described. 11 The endpoint of CPVI or cryoballoon catheter ablation was bidirectional conduction block. A cavotricuspid isthmus (CTI) bidirectional block, super vena cava isolation (SVCI), linear ablation of LA roof or mitral isthmus, and complex fractionated atrial electrograms (CFAE) were selected performed as additional ablation. Pharmacological (ibutilide or aminodarone) or electrical cardioversion (ECT) was performed during the procedure when it was necessary. NPAF: AADs failed, refractory to anti-arrhythmic drug; AF history, refers time that AF has been diagnosed; BBB, bundle branch block; BMI, body mass index; BNP, B-type natriuretic peptide; CAD, coronary artery disease; Cryoballoon, cryoballoon ablation; CRP, C reactive protein; CTI, cavo-tricuspid isthmus ablation; CFAE, complex fractionated atrial electrogram ablation; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; ECV, electrical cardioversion; ER, early recurrence; EF, ejection fraction; FU, follow up period; eGFR, estimated glomerular filtration rate; HF, history of congestive heart failure; LAD, left atrial diameter; Linear, linear ablation; Pharm CV, pharmaceutical cardioversion; PVI, pulmonary vein isolation; TIA, transient ischemic attack; SCVI, superior vena cava ablation; ST, with smart touch ablation catheter. Chi-square test and independent t test. *Statistically significant P < 0.05. Variables are n (%) or mean ± SD.
| Follow up

| Statistical analysis
All continuous variables were presented as mean ± standard deviation and categorical variables were summarized as percentages.
The area under ROC curve (AUC) was used to test the predictive probability of biomarkers or their combination for AF recurrence.
Cut-off analyses were also performed with specificity and sensitivity calculated. ANOVA or Chi-square tests were used to test the differences in continuous or categorical variables among four groups with none, 1, 2, or 3 abnormal biomarkers. The association of the clinical variables with AF recurrence was analyzed using univariate and multivariate Cox regression models. Cox proportional-hazards models with time-dependent covariates for changing biomarker combination and AF recurrence was built to evaluate the independent effect of different biomarker combination on out- Clinical, biochemical, echocardiographic, and procedural characteristics of patients with AF recurrence or not are summarized in Table 1 . Patients with AF recurrence were older and had larger left atrial size, much more cardiac diseases or stroke, much more additional ablation, higher serum BNP and CRP, lower eGFR compared to those without recurrence (all P < 0.05).
| Biomarkers and AF recurrence
Based on differences seen on the univariate comparisons in Table 1 , multivariate regression analysis using the variables that were significant found only that age, AF types, prior history of coronary artery disease (CAD), LAD, early recurrence (ER), BNP, and CRP emerged as independent risk factors of AF recurrence, as was low eGFR (see Table 2 ).
Using ROC analysis for biomarkers as continuous variables, good predictive ability for AF recurrence was evident for eGFR (AUC 0.74, CI 0.71-0.77, P < 0.001), CRP (AUC 0.82, CI 0.79-0.85, P < 0.001) and BNP (AUC 0.90, CI 0.88-0.92, P < 0.001) (Figure 1 ).
Cut-off analyses gave eGFR, CRP, and BNP values of 82.5 mL/min/ 1.73 m 2 (specificity 64%, sensitivity 74%), 1.6 mg/dL (specificity 76%, sensitivity 79%), and 237.45 pg/mL (specificity 79%, sensitivity 87%), respectively, as biomarker levels that were predictive of AF recurrence.
Using these cut-off values to categorize normal or abnormal values, covariate regression analysis gave hazard ratios for eGFR (HR 2.07, CI 1.63-2.65, P = 0.001), CRP (HR 3.04, CI 2.32-3.99, P = 0.001), and BNP (HR 7.0, CI 5.05-9.72, P = 0.001) as independent predictors for AF recurrence (see Table 3 ). ROC analysis demonstrated good predictive ability of the categorized "cut-off val- tively, with differences that were significant (P < 0.001, Delong's method) (see Figure 3 ).
We scored patients as having 0, 1, 2, and 3 points for those with none, 1, 2, or 3 abnormal biomarker levels. With increasing points, patients had corresponding increases in AF recurrence events (trend P < 0.001), ER events (trend P < 0.001) and left atrial size (trend P < 0.001) (see Table 4 ). History of various cardiovascular comorbidities (trend, P < 0.001) also increased with increasing points.
Increasing points were associated with more pharmacological or electricial cardioversion, as well as linear or complex fractionated atrial electrograms (CFAE) ablation (all P < 0.001; see Table 4 ).
T A B L E 3 Cut-off value of biomarkers and their predictive value for AF recurrence under multivariate analysis
Risk factors
Hazard ratio (95% CI) P value* When adjusted by gender, age, history of prior stroke/TIA, heart failure, coronary artery disease, hypertension, diabetes mellitus, nonparoxysmal AF, early recurrence, left atrial diameter, and body mass index, multivariate Cox regression analysis showed that patients with two or three abnormal biomarkers had rapid increasing risk of AF recurrence (all P < 0.01) when compared to those without abnormal biomarkers (see Table 5 ). Using multivariate analysis, patients without abnormal biomarkers had a lower risk of AF recurrence (P < 0.01) with no statistically significant association in those with only one abnormal biomarker (P > 0.05). Apart from two or multiple abnormal biomarkers, those patients at younger age, with large left atrial diameter and early recurrence were independent predictors of AF recurrence on multivariate analysis (P < 0.05). Nonparoxysmal AF was not an independent predictor using multivariate analysis
Kaplan-Meier analysis demonstrated that the sinus rhythm maintenance rate decreased sharply with increasing "abnormal biomarker"
points while the risk of AF recurrence increased (see Figure 4) . Similar findings were evident in the subgroups of patients with paroxysmal or nonparoxysmal AF, where increasing "abnormal biomarker" points were related to more AF recurrence (see Figures 5, 6 ).
| DISCUSSION
In this study, of the impact on arrhythmia outcome by using three biomarkers our main findings are as follows: (a) 
<0.01
BMI, body mass index; BNP, B-type natriuretic peptide; CAD, coronary artery disease; Cryoballoon, cryoballoon ablation; CRP, C reactive protein; CTI, cavo-tricuspid isthmus ablation; CFAE, complex fractionated atrial electrogram ablation; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; ECV, electrical cardioversion; ER, early recurrence; EF, ejection fraction; FU, follow up period; eGFR, estimated glomerular filtration rate; HF, history of congestive heart failure; LAD, left atrial diameter; Linear, linear ablation; NPAF, non-paroxysmal atrial fibrillation; Pharm CV, pharmaceutical cardioversion; PVI, pulmonary vein isolation; Re, recurrence; TIA, transient ischemic attack; SCVI, superior vena cava ablation. Variables are n (%) or mean ± SD; Chi-square test and ANOVA test; *Statistically significant P < 0.05. a Group 1, no abnormal biomarkers (0 point); Group 2, one abnormal biomarker (1 point); Group 3, two abnormal biomarkers (2 points); Group 4, three abnormal biomarkers (3 points). Abnormal biomarker cut-offs, as defined in Table 3 .
b
Compared to other three groups.
CRP, and eGFR were incrementally additive to clinical risk factors in a cumulative manner to improve prediction of arrhythmia recurrence post-CA of AF. Similar findings were evident in the subgroups of patients with paroxysmal or nonparoxysmal AF, where increasing "abnormal biomarker" points were related to more AF recurrence.
| Biomarkers and catheter ablation outcome
Biomarkers especially inflammatory indices have been related to the AF relapse post CA. Many inflammatory factors, including CRP, 12, 13 TNF-α, ET-1, 14 CD 36, 7 and heat shock protein, 15 as well as other Table 3 . Adjusted for gender, body mass index, COPD, smoking, alcohol consumption, presence of coronary artery disease, heart failure, hypertension, diabetes mellitus, stroke, transient ischemic attack, and nonparoxysmal AF. ) were all independent predictors for AF recurrence of our cohort. Although all three biomarkers were individual predictors, the present study also shows how these biomarkers are additive in combination, for predicting AF recurrence post-CA.
To evaluate the additive predictive ability in combination of BNP, CRP, and eGFR, we also scored patients when they had one or more "abnormal" biomarkers. Patients with different points presented numbers of "abnormal" biomarkers and the association of the points and the AF recurrence illustrates the additive predictive ability of biomarkers in combination. The cut-off value of biomarker was used to divide serum level as "normal" or "abnormal" in our study population, and we recognize that a local laboratory "abnormal cutoff value" could be different based on different cohorts. For example, in our cohort, BNP ≥ 237.45 pg/mL was defined as "abnormal", while in another study cohort, "abnormal" BNP was defined as ≥ 423.20 pg/mL. In this study, patients undergoing CA had increasing risk of AF recurrence when quantity of abnormal biomarkers was increased.
Patients with more abnormal biomarkers required more additional ablation or cardioversion during the procedure which perhaps implies the presence of a more complicated AF substrate.
Our findings show that baseline biomarkers levels measured before an ablation procedure have good predictive value for AF recurrence postablation. Most clinical scores derived for predicting AF recurrence include important risk factor(s) for early recurrence, allows predict only following the ablation procedure; nevertheless, baseline biomarkers levels may be used as an alternative tool for estimation of the likelihood of AF recurrence, and help with patients selection.
| Limitations
This was a single centre, retrospective, and observational study.
While patient follow-up was based on symptoms, 12 lead ECG and 24 hour Holter ECG examinations during follow-up visits, asymptomatic AF might still be missed. The follow-up period was limited, and patients undergoing multiple ablation procedures were not included. About 1% patients of this cohort had accepted ablation elsewhere before the enrolment which might also have implications for ablation outcomes, but our objective was to study a complete "real world" cohort of patients undergoing CA our centre-not to focus on selected subgroups which may be small and underpowered. We do recognize that recurrent risk factors of PAF and NPAF may be different as well as the impact of each biomarker(s) in combination in these separate subgroups.
Nevertheless, we are clearly underpowered for detailed analyses of the PAF and NPAF subgroups separately, and our subgroup analyses in relation to recurrences with increasing "abnormal biomarker" points ( Figures 5 and 6 ) should only be regarded as exploratory.
In conclusion, multiple biomarkers, including BNP, CRP, and 
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